Trials in rheumatoid arthritis: Choosing the right outcome measure when minimal disease is achievable

Annals of the Rheumatic Diseases

Volumn 67, Issue 5, 2008, Pages 580-583

  Felson, David T ^a   Zhang, Bin ^a   Siegel, Jeffrey N ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; CYCLOSPORIN; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; HEART INFARCTION; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; PATIENT SELECTION; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 42449088097     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.079632     Document Type: Review

References (20)

1. O'Dell JR. The best way to treat early rheumatoid arthritis. Ann Intern Med 2007;146:459-60.
2. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatic arthritis (the TICORA study): a single-blind randomised controllled trial. Lancet 2004;364:263-9.
3. Goekoop-Ruiterman Y, de Vries-Bouwstra J, Allaart CF, Van Zeben D, Kerstens P, Hazes MW, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study). A randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
4. Anderson JJ, Bolognese JA, Felson DT. Effects of disease duration and outcome definition on the power of rheumatoid arthritis clinical trials. Arthritis Rheum 2002;46:S520.
5. Vanags D, Williams B, Johnson B, Hall S, Nash P, Taylor A, et al. Theraputic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 2006;368:855-63.
6. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thmson D, Kishimoto T. Double blind randomized controlled clinical trial of the interlukein-6 receptor, antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817- 29.
7. Kremer JM, Genant HK, Moreland LW, Rusell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate resistant active rheumatoid arthritis. Ann Int Med 2006;144:865- 76.
8. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Arthritis Rheum 2006;54:1063-74.
9. Emery P, Fleischman R, Filipowickz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The effficacy and safety of rituxximab in patients with active rheumatoid arhtritis despite methotrexate treatment. Arthritis Rheum 2006;54:1390-400.
10. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, et al. Combination treatment with methotrexate, cyclosporine and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis Arthritis Rheum 2006;54:1401-9.
11. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pevelka K, Van Vollenhoven R, et al. A multicenter, randomized, double-blinded clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, agressive rheumatoid arthritis whohad not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
12. Van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478-83.
13. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patietns with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006;65:1357-62.
14. Lau J, Ioannidis JPA, Schmid C. Summing up evidence: one answer is not always enough. Lancet 1998;351:123-7.
15. Cardiovascular Disease Statistics. http://www.americanheart.org/ presenter.jhtml?identifier=4478 (accessed 28 December 2007).
16. Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ 1988;317:1170-1.
17. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
18. Anderson JJ, Bolognese JA, Felson DT. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthritis Rheum 2003;48:3031-8.
19. Pincus T, Amara I, Koch GG. Continuous indices of core data set measures in rheumatoid arthritis clinical trials. Lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum 2005;52:1031-6.
20. Pincus T, Sokka T, Kautiainen H. Patients seen for rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;54:1009-19.